Research article summary (published 29 Nov 2009):

Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up.

Full Abstract

BACKGROUND: Kinsbourne syndrome or opsoclonus myoclonus syndrome (OMS) is characterized by rapid, involuntary, irregular conjugate eye movements (opsoclonus), myoclonic jerking of the limbs and trunk, ataxia, and behavioral disturbances. In general, the outcome of neurologic and behavioral symptoms is poor. Studies on quality of life (Qol) and recovery after very long-term follow-up of children with OMS are lacking. METHODS: We studied long-term cancer survival, neurologic recovery, and Qol of a consecutive series of eight patients with OMS that were treated in our center. Two cross-sectional follow-up evaluations were conducted at a 3-year interval (T1 and T2). RESULTS: In four out of eight children with OMS a neuroblastoma (NBL) was diagnosed and surgically removed completely. All children received immuno-modulatory therapy, consisting of prednisone (three children), prednisone and ACTH (four children), or prednisone, ACTH, and gammaglobulin (one child). At T1, median follow-up time was 9.5 years (range 3-14 years) after OMS onset and at T2, 11.6 years (range 6-17 years). Neurologic functioning improved in all children, reflected by a significant improvement of the mean Z-score in the motor domain of the Qol questionnaire at T2 as compared to T1. In contrast, seven children continued to have a severe developmental delay at T2. No significant difference in any of the variables was found between NBL survivors and OMS patients without NBL. CONCLUSION: Cognitive and behavioral impairments and not a motor impairment, such as ataxia, appear to be predominant at long-term in children with OMS.

Author information

Author/s: Catsman-Berrevoets, Coriene E (CE); Aarsen, Femke K (FK); van Hemsbergen, Marloes L C (ML); van Noesel, Max M (MM); Hakvoort-Cammel, Frederique G A J (FG); van den Heuvel-Eibrink, Marry M (MM);

Affiliation: Department of Pediatric Neurology, Erasmus MC/Sophia Children's Hospital, Rotterdam, the Netherlands. c.catsman(-atsign-)erasmusmc.nl

Journal and publication information

Publication Type: Journal Article

Journal: Pediatric blood & cancer (Pediatr Blood Cancer), published in United States. (Language: eng)

Reference: 2009-Dec; vol 53 (issue 6) : pp 1048-53

Dates: Created 2009/09/16; Completed 2009/10/13;

PMID: 19672966, status: MEDLINE (last retrieval date: 10/13/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Adolescent Adrenocorticotropic Hormone - therapeutic use Child Child, Preschool Cognition Disorders - etiology Female Follow-Up Studies Humans

Male Mental Disorders - etiology Opsoclonus-Myoclonus Syndrome - complications; psychology Paraneoplastic Syndromes, Nervous System - physiopathology; psychology Prednisone - therapeutic use Quality of Life Questionnaires gamma-Globulins - therapeutic use

Associated Chemicals: gamma-Globulins (0) ; Prednisone (53-03-2) ; Adrenocorticotropic Hormone (9002-60-2)

Related articles

These are the highest related articles currently in the database:

• Paraneoplastic opsoclonus-myoclonus ataxia associated with non-small-cell lung carcinoma. 9 Jul 2008
• T-lymphocyte production, function, and death in children who recovered from opsoclonus-myoclonus syndrome. 30 Dec 2006
• Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. 7 Aug 2008
• Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. 30 Jan 2008
• Neuro-ophthalmologic manifestations of paraneoplastic syndromes. 28 Feb 2008
• False-positive metaiodobenzylguanidine scan for neuroblastoma in a child with opsoclonus-myoclonus syndrome treated with adrenocorticotropic hormone (acth). 29 Jun 2006
• [Opsoclonus-myoclonus syndrome associated with Mycoplasma pneumoniae infection] 29 May 2007
• Opsoclonus-myoclonus syndrome associated with group a streptococcal infection. 30 Mar 2007
• Neuroblastoma found in a 4-year-old after rituximab therapy for opsoclonus-myoclonus. 30 Aug 2006
• Long-term survival in paraneoplastic opsoclonus-myoclonus syndrome associated with small cell lung cancer. 28 Feb 2008

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.